BI 685509 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 1 |
51. Scleroderma
Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05559580 (ClinicalTrials.gov) | November 24, 2022 | 26/9/2022 | A Study in People With Systemic Sclerosis to Test Whether BI 685509 Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms | A Phase II, Randomised, Placebo-controlled, Double-blind, Parallel Group, Efficacy and Safety Study of at Least 48 Weeks of Oral BI 685509 Treatment in Adults With Early Progressive Diffuse Cutaneous Systemic Sclerosis | Scleroderma, Systemic | Drug: BI 685509;Drug: Placebo | Boehringer Ingelheim | NULL | Recruiting | 18 Years | N/A | All | 200 | Phase 2 | Australia;Austria;Belgium;Canada;China;Czechia;Finland;France;Greece;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;New Zealand;Poland;Romania;Singapore;Spain;Sweden;Thailand |